<scp>FBP1</scp> induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer

Published:2022-12-16 Issue:4 Volume:14 Page:371-380
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Li Jian¹,Dai Ping¹,Sun Jing¹,Yu Wenyan¹,Han Wei¹,Li Kaichun¹^ORCID

Affiliation:

1. Department of Oncology Shanghai Fourth People's Hospital, Tongji University School of Medicine Shanghai China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14750

Reference42 articles.

1. Cancer statistics, 2019

2. Age-period-cohort analysis of lung cancer mortality in China and Australia from 1990 to 2019

3. Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

4. Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

5. Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-01-09

2. The complementary and alternative roles of elemene injection in cancer: An umbrella review;Pharmacological Research;2023-12

3. β‐elemene enhances cisplatin sensitivity of non‐small cell lung cancer cells via the miR‐17‐5p/STAT3 axis;Chemical Biology & Drug Design;2023-11-16

4. Elemene Antitumor Drugs Development Based on “Molecular Compatibility Theory” and Clinical Application: A Retrospective and Prospective Outlook;Chinese Journal of Integrative Medicine;2023-10-14

5. Targeted drug delivery systems for elemene in cancer therapy: The story thus far;Biomedicine & Pharmacotherapy;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3